Volume 5.11 | Mar 28

Prostate Cell News 5.11 March 28, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Targeting Autophagy Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells and Improves Therapeutic Response in a Xenograft Model
Androgen deprivation or treatment with androgen receptor signaling inhibitor, Enzalutamide or bicalutamide induced autophagy in androgen-dependent and in castration-resistant prostate cancer cell lines. [Oncogene]
Full Article
[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Loss of Dlg5 Expression Promotes the Migration and Invasion of Prostate Cancer Cells via Girdin Phosphorylation
Researchers demonstrated that Dlg5 is frequently downregulated in prostate cancer. They showed that Dlg5 is involved in the regulation of cell migration and cancer cell invasion. [Oncogene] Abstract

Autophagic Flux Determines Cell Death and Survival in Response to Apo2 Ligand/TRAIL (Dulanermin)
Researchers investigated whether SQSTM1/p62 overexpression, as a marker of autophagic flux, was related to aggressiveness of human prostate cancer (PCa) and whether autophagy regulated the treatment response in sensitive but not resistant PCa cell lines. [Mol Cancer] Full Article

Tissue Transglutaminase Expression Promotes Castration-Resistant Phenotype and Transcriptional Repression of Androgen Receptor
Investigators report that human prostate cancer cell lines with low expression of androgen receptor had high basal levels of tissue transglutaminase expression. [Eur J Cancer] Abstract

The N-Terminal Domain of the Androgen Receptor Drives Its Nuclear Localization in Castration-Resistant Prostate Cancer Cells
Since the N-terminal domain (NTD) of androgen receptor (AR) plays a role in transactivation under androgen-depleted conditions, scientists investigated the role of NTD in AR nuclear localization in castration-resistant prostate cancer. [J Steroid Biochem Mol Biol] Abstract

NVP-BEZ235, A Dual PI3K/mTOR Inhibitor, Induces Cell Death through Alternate Routes in Prostate Cancer Cells Depending on the PTEN Genotype
Researchers investigated how the PTEN genotype affected the antitumor effect of NVP-BEZ235 in human prostate cancer cells. [Apoptosis] Abstract

Celastrol Blocks Interleukin-6 Gene Expression via Downregulation of NF-?B in Prostate Carcinoma Cells
Scientists evaluated the molecular mechanisms of celastrol on cell proliferation and interleukin-6 gene expression in prostate carcinoma cells. [PLoS One] Full Article

Gene Expression Profiling Associated with Angiotensin II Type 2 Receptor-Induced Apoptosis in Human Prostate Cancer Cells
Researchers used PCR Array analysis to determine the gene and microRNA expression profiles in human prostate cancer cell lines transduced with angiotensin II type 2 receptor recombinant adenovirus. [PLoS One] Full Article

CLINICAL RESEARCH

Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Scientists assessed tumor cells from patients with prostate cancer participating in a Phase II neoadjuvant docetaxel and androgen deprivation trial to identify mediators of resistance. [Mol Cancer Ther] Abstract

The Impact of Pathologic Staging on the Long-Term Oncologic Outcomes of Patients with Clinically High-Risk Prostate Cancer
In the prostate-specific antigen screening era, approximately 15% of US men still present with clinically high-risk prostate cancer (PC). However, high-risk PC may be downgraded/downstaged at radical prostatectomy (RP), making additional therapy unnecessary. The authors tested the oncologic outcomes in men with clinically high-risk disease stratified on RP pathology. [Cancer] Abstract

Ganglioside Disialosyl Globopentaosylceramide Is an Independent Predictor of PSA Recurrence-Free Survival following Radical Prostatectomy
Researchers investigated disialosyl globopentaosylceramide (DSGb5) expression in prostate tissues and the relationship between DSGb5 expression and clinicopathological characteristics of prostate cancer patients. [Prostate Cancer Prostatic Dis] Abstract

Free Cell Stem Cell Poster: Directed Differentiation of ESCs/iPSCs
 
REVIEWS
Androgen Receptor Antagonists for Prostate Cancer Therapy
With recent evidence that castrate resistant prostate cancer is far from androgen receptor (AR)-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach. [Endocr Relat Cancer] Abstract

Novel Bone-Targeting Agents in Prostate Cancer
The authors provide an overview of the multiple emerging novel bone-targeted therapies in prostate cancer. [Prostate Cancer Prostatic Dis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Cell Line Development Asia 2014
 
INDUSTRY NEWS
Exelixis Provides Update on Ongoing COMET-1 Phase III Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer
Exelixis, Inc. announced that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 Phase III pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. [Exelixis, Inc.] Press Release

Astellas Announces Marketing Approval in Japan for XTANDI® (Enzalutamide) Capsules, a Prostate Cancer Treatment
Astellas Pharma Inc. announced that Astellas has obtained the marketing approval of oral androgen receptor signaling inhibitor, XTANDI® capsules 40mg for the treatment of patients with castration-resistant prostate cancer in Japan. [Astellas Pharma Inc.] Press Release

$4.25 Million Grant Awarded to Rutgers Cancer Institute of New Jersey and University of Wisconsin Carbone Cancer Center to Develop Innovative Clinical Trials
Dr. DiPaola, who was just awarded a $4.25 million grant (UM1CA186716) by the National Cancer Institute of the National Institutes of Health to support a precision experimental therapeutics endeavor, will collaborate with investigators from the University of Wisconsin Carbone Cancer Center on the research that will have a nationwide reach. [Rutgers Cancer Institute of New Jersey] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 18th International Congress on In Vitro Toxicology (ESTIV2014)
June 10-13, 2014
Egmond aan Zee, Netherlands

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellows – Small-Molecule Drugs in the Treatment of Prostate Cancer Bone Metastasis (Georgia Regents University Cancer Center)

Studentship – Targeting WW Domain Function in Ubiquitin Ligases Overexpressed in Prostate Cancer (University of East Anglia)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Cancer (Mayo Clinic- Rochester)

Postdoctoral Fellow – Biomarker Discovery In Prostate Cancer (University of California, San Francisco)

Postdoctoral Position – Cancer Biology/Genomics (Weill Cornell Medical College)

Postgraduate Position – Chemokine Receptor Induced Cell Migration (University of East Anglia)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us